GENENTECH, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
A Study of the Safety and Pharmacology of MetMAb (PRO143966), a Monovalent Antagonist Antibody to the Receptor C-Met, Administered Intravenously in Patients With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2010-02-17
- Last Posted Date
- 2017-05-19
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT01068977
A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)
- First Posted Date
- 2010-02-01
- Last Posted Date
- 2020-01-13
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 413
- Registration Number
- NCT01059630
- Locations
- 🇺🇸
South Texas Inst of Cancer, Corpus Christi, Texas, United States
🇺🇸University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
A Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0941 and the Effect of Food and Proton Pump Inhibition on GDC-0941 Tablet Pharmacokinetics in Healthy Volunteers
- First Posted Date
- 2009-10-21
- Last Posted Date
- 2017-02-09
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT00999128
- Locations
- 🇺🇸
Genentech Trial Information Support, South San Francisco, California, United States
A Study of the Safety, Tolerability, Pharmacokinetics, and Bioavailability of IV and SC MABT5102A in Healthy Volunteers
- First Posted Date
- 2009-10-20
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT00997919
Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2009-10-16
- Last Posted Date
- 2016-12-30
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 178
- Registration Number
- NCT00996892
A Study of the Hedgehog Pathway Inhibitor GDC-0449 in Healthy Female Subjects of Non-Childbearing Potential
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: GDC-0449 oral capsules (non-labeled)Drug: CDC-0449 oral suspension (labeled)Drug: GDC-0449 IV injection (labeled)
- First Posted Date
- 2009-10-08
- Last Posted Date
- 2017-06-26
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT00991718
A Study of huMAb OX40L in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic Asthma
- First Posted Date
- 2009-09-24
- Last Posted Date
- 2016-08-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT00983658
A Study of the Safety and Pharmacokinetics of GDC-0152, Administered Intravenously to Patients With Locally Advanced or Metastatic Malignancies
- First Posted Date
- 2009-09-15
- Last Posted Date
- 2017-06-21
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT00977067
A Study of the Safety and Pharmacology of GDC-0941 in Combination With Erlotinib in Patients With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer, Solid Cancers
- Interventions
- First Posted Date
- 2009-09-11
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 58
- Registration Number
- NCT00975182
A Study of the Safety and Pharmacology Of PI3-Kinase Inhibitor GDC-0941 In Combination With Either Paclitaxel And Carboplatin (With or Without Bevacizumab) or Pemetrexed, Cisplatin, And Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer
Phase 1
Completed
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2009-09-10
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 65
- Registration Number
- NCT00974584
© Copyright 2025. All Rights Reserved by MedPath